Arcus Biosciences, Inc. (NYSE:RCUS) CEO Buys $201,564.00 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CEO Terry J. Rosen purchased 19,800 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The shares were acquired at an average cost of $10.18 per share, with a total value of $201,564.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. This represents a 0.78 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Arcus Biosciences Stock Up 10.2 %

Shares of NYSE RCUS opened at $10.89 on Friday. Arcus Biosciences, Inc. has a 1 year low of $9.85 and a 1 year high of $20.00. The firm’s 50-day moving average is $13.37 and its 200-day moving average is $15.40. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $1.14 billion, a PE ratio of -3.46 and a beta of 0.84.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.14. The firm had revenue of $36.00 million for the quarter, compared to analysts’ expectations of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. Equities analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Wall Street Analyst Weigh In

RCUS has been the topic of several research analyst reports. Bank of America decreased their target price on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Wednesday, February 19th. HC Wainwright raised shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $18.00 to $24.00 in a report on Wednesday. Morgan Stanley lowered their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Finally, Wedbush reiterated an “outperform” rating and set a $36.00 target price on shares of Arcus Biosciences in a research report on Thursday, November 7th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Arcus Biosciences presently has an average rating of “Buy” and an average price target of $30.25.

Institutional Investors Weigh In On Arcus Biosciences

A number of institutional investors have recently made changes to their positions in RCUS. R Squared Ltd acquired a new position in Arcus Biosciences in the fourth quarter valued at about $26,000. Point72 Hong Kong Ltd bought a new stake in shares of Arcus Biosciences in the 3rd quarter valued at about $47,000. Lazard Asset Management LLC raised its position in shares of Arcus Biosciences by 3,321.3% in the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock valued at $93,000 after acquiring an additional 6,078 shares during the period. US Bancorp DE boosted its stake in Arcus Biosciences by 2,432.0% during the 4th quarter. US Bancorp DE now owns 6,887 shares of the company’s stock worth $103,000 after acquiring an additional 6,615 shares during the last quarter. Finally, Quest Partners LLC boosted its stake in Arcus Biosciences by 40,904.3% during the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock worth $144,000 after acquiring an additional 9,408 shares during the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.